Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 5, 2010, Pages 560-570

  Hesseling, A C ^a   Walzl, G ^a   Enarson, D A ^b   Carroll, N M ^a   Duncan, K ^c,d   Lukey, P T ^c   Lombard, C ^e   Donald, P R ^a   Lawrence, K A ^a   Gie, R P ^a   Helden, P D Van ^a   Beyers, N ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c GLAXOSMITHKLINE   (United Kingdom)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Recurrence; Sputum conversion; Time to detection (TTD); Tuberculosis relapse

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BODY MASS; CLINICAL TRIAL; DISEASE MARKER; FEMALE; HUMAN; INFECTION RISK; LUNG CAVITY; LUNG PARENCHYMA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NON HIV INFECTED PATIENT; PATIENT; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; SEX DIFFERENCE; SHORT COURSE THERAPY; SPUTUM CULTURE; SPUTUM SMEAR; TIME; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; PROSPECTIVE STUDIES; RECURRENCE; REGRESSION ANALYSIS; RISK FACTORS; SEX FACTORS; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 77950913811     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Benator D, Bhattacharya M, Bozeman L et al.; Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528-534.
2. Mitchison D A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months [letter]. Am Rev Respir Dis 1993; 147: 1062-1063.
3. Aber V R, Nunn A J. Short-term chemotherapy of tuberculosis: factors affecting relapse following short term chemotherapy. Bull Int Union Tuberc 1978; 53 (4): 276-280.
4. Wallis R S, Perkins M, Phillips M, et al. Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 2000; 161: 1076-1080, 2000. (Pubitemid 30243811)
5. Epstein M D, Schluger N W, Davidow A L, Bonk S B, Rom W N, Hanna B. Time to detection of M. tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1997; 113: 379-386. (Pubitemid 28110014)
6. Hasegawa N, Miura T, Ishizaka A, Yamaguchi K, Ishii K. Detection of mycobacteria in patients with pulmonary tuberculosis undergoing chemotherapy using MGIT and egg-based solid medium culture systems. Int J Tuberc Lung Dis 2002; 6: 447-453. (Pubitemid 34492169)
7. Wallis R S, Patil S, Cheon S H, et al. Drug tolerance in Myco-bacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 2600-2606.
8. Pheiffer C, Carroll N M, Beyers N, et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis 2008; 12: 792-798. (Pubitemid 351976711)
9. South Africa Department of Health, Provincial Government of the Western Cape, City of Cape Town/Metropole Region. TB Control Programme progress report 1997-2002. Cape Town, South Africa: South Africa Department of Health, 2003. http://www.hst.org.za/publications/618 Accessed September 2009.
10. South African Department of Health. National HIV and Syphilis antenatal seroprevalence survey 2002. Pretoria, South Africa: Directorate, Health Systems Research, 2003. www.doh. gov.za/docs/reports/2002/hiv-syphilis.pdf Accessed September 2009.
11. Classen C N, Warren R, Richardson M, et al. Impact of social interactions in the community on the transmission of tuberculosis in a high incidence area. Thorax 1999; 54: 136-140. (Pubitemid 29101357)
12. Verver S, Warren R M, Munch Z, et al. Transmission of tuberculosis in a high incidence urban community in South Africa. Int J Epidemiol 2004; 33: 351-357. (Pubitemid 38578835)
13. Simon G. Radiology in epidemiological studies and some therapeutic trials. BMJ 1966; 2: 491-494.
14. Enarson D A, Rieder H L, Arnadottir T, Trébucq A. Tuberculosis guide for low income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
15. Carroll N M, Richardson M, Engelke E, de Kock M, Lombard C, van Helden P D. Reduction of the rate of false-positive cultures of Mycobacterium tuberculosis in a laboratory with a high culture positivity rate. Clin Chem Lab Med 2002; 40: 888-892. (Pubitemid 35277414)
16. Salman S H. BACTEC 460TB Systems product and procedure manual. Sparks, MD, USA: Becton Dickinson Diagnostic Instrument Systems, 1996.
17. Warren R M, van der Spuy G D, Richardson M, et al. Evolution of the IS6110-based restriction fragment length polymorphism pattern during the transmission of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 1277-1282. (Pubitemid 34279889)
18. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international def nitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5: 213-215.
19. Wallis R S, Perkins M, Phillips M, et al. Induction of the antigen 85 complex of M. tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis. J Infect Dis 1998; 178: 1115-1121. (Pubitemid 28452206)
20. Tuberculosis Division, International Union Against Tuberculosis and Lung Disease. Tuberculosis bacteriology\priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 2005; 9: 355-361.
21. Steingart K R, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6: 664-674. (Pubitemid 44462695)
22. Gopi P G, Chandrasekaran V, Subramani R, et al. Association of conversion and cure with initial smear grading among new smear positive pulmonary tuberculosis patients treated with Category I regimen. Indian J Med Res 2006; 123: 807-814. (Pubitemid 44269948)
23. Rustomjee R, Lienhardt C, Kanyok T, et al; Gatif oxacin for TB (OFLOTUB) study team. A Phase II study of the sterilising activities of of oxacin, gatif oxacin and moxif oxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138. (Pubitemid 351212403)
24. Dorman S E, Johnson J L, Goldberg S, et al; Tuberculosis Trials Consortium. Substitution of moxif oxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
25. Perrin F M, Lipman M C, McHugh T D, Gillespie S H. Bio-markers of treatment response in clinical trials of novel anti-tuberculosis agents. Lancet Infect Dis 2007; 7: 481-490. (Pubitemid 46962336)
26. Wallis R S. Surrogate markers to assess new therapies for drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2007; 5: 163-168.
27. Brindle R, Odhiambo J, Mitchison D. Serial counts of Myco-bacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1: 2. (Pubitemid 38729368)
28. Warren R M, Victor T C, Streicher E M, et al. Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 2004; 169: 6120-6124.
29. Carroll N M, Uys P, Hesseling A C, et al. Prediction of delayed treatment response in pulmonary tuberculosis: use of time to positivity values of Bactec cultures. Tuberculosis (Edinb) 2008; 88: 624-630.